伊匹木单抗、纳武利尤单抗和维布妥昔单抗联合方案治疗复发或难治性霍奇金淋巴瘤:开放标签、多中心1/2期试验的1期结果
这项多中心开放标签1/2期试验评估维布妥昔单抗联合伊匹木单抗或纳武利尤单抗或两者联合治疗复发或难治性霍奇金淋巴瘤的安全性和活性,采用3+3剂量递增设计。共入组64例患者,61例可评估,确定各联合方案最大耐受剂量,三种方案总缓解率分别为76%、89%和82%。
要点
- 维布妥昔单抗联合纳武利尤单抗或三联方案在复发/难治性霍奇金淋巴瘤中显示较高总缓解率。
- 伊匹木单抗组3-4级治疗相关不良事件10例(43%),纳武利尤单抗组3例(16%),三联组11例(50%)。
- 治疗相关死亡共2例(3%),分别发生在纳武利尤单抗组和三联组各1例。
核心结论
- 三种联合方案的活性和毒性存在明显差异。
- 两种最具活性的方案——维布妥昔单抗联合纳武利尤单抗和三联方案——的耐受性和初步活性正在随机2期试验(NCT01896999)中比较。
研究设计与样本
- 多中心、开放标签、1/2期试验,采用3+3剂量递增设计并设扩展队列。
- 纳入年龄18岁及以上、至少一线治疗后复发或难治的霍奇金淋巴瘤患者,ECOG体能状态评分2或以下,器官和骨髓功能充足,无肺功能障碍。
- 2014年3月7日至2017年12月28日共入组64例患者,2例伊匹木单抗组和1例纳武利尤单抗组患者入组后因不符合条件被排除,61例可评估。
主要发现
- 共报告6例剂量限制性毒性,发生在4例患者中;队列B、E和H的剂量被确定为最大耐受剂量,随后患者以这些方案入组扩展队列C、F和I。
- 伊匹木单抗组3-4级治疗相关不良事件10例(43%),纳武利尤单抗组3例(16%),三联组11例(50%);64例中8例(13%)报告皮疹,结肠炎、胃炎、胰腺炎、关节炎和糖尿病酮症酸中毒各发生于1例(2%)患者。
- 治疗相关死亡2例(3%),纳武利尤单抗组1例,三联组1例。
- 总缓解率:伊匹木单抗组76%(95%CI 53-92),纳武利尤单抗组89%(95%CI 65-99),三联组82%(95%CI 60-95);完全缓解率:伊匹木单抗组57%(95%CI 34-78%),纳武利尤单抗组61%(95%CI 36-83%),三联组73%(95%CI 50-89%)。
- 中位随访:伊匹木单抗组2.6年(IQR 1.8-2.9),纳武利尤单抗组2.4年(IQR 2.2-2.6),三联组1.7年(IQR 1.6-1.9);中位无进展生存期:伊匹木单抗组1.2年(95%CI 1.7-未达到),其他两组未达到;所有组中位总生存期均未达到。
关键数值与推荐
- 剂量递增阶段六个队列:伊匹木单抗组固定维布妥昔单抗1.8 mg/kg联合伊匹木单抗1 mg/kg(队列A)或3 mg/kg(队列B);纳武利尤单抗组固定纳武利尤单抗3 mg/kg联合维布妥昔单抗1.2 mg/kg(队列D)或1.8 mg/kg(队列E);三联组固定纳武利尤单抗3 mg/kg和伊匹木单抗1 mg/kg联合维布妥昔单抗1.2 mg/kg(队列G)或1.8 mg/kg(队列H)。
- 扩展阶段以队列B、E和H相同剂量入组额外患者。
- 所有药物静脉给药;维布妥昔单抗和纳武利尤单抗每3周给药,伊匹木单抗在伊匹木单抗组每6周给药、在三联组每12周给药。
- 最大耐受剂量:队列B(维布妥昔单抗1.8 mg/kg联合伊匹木单抗3 mg/kg)、队列E(纳武利尤单抗3 mg/kg联合维布妥昔单抗1.8 mg/kg)、队列H(纳武利尤单抗3 mg/kg和伊匹木单抗1 mg/kg联合维布妥昔单抗1.8 mg/kg)。
临床怎么用
- 原文未据此给出推荐。
- 作者指出两种最具活性的方案——维布妥昔单抗联合纳武利尤单抗和三联方案——的耐受性和初步活性正在随机2期试验(NCT01896999)中比较。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recognising that the immune suppressive microenvironment promotes tumour growth in Hodgkin lymphoma, we hypothesised that activating immunity might augment the activity of targeted chemotherapy. We evaluated the safety and activity of combinations of brentuximab vedotin with nivolumab or ipilimumab, or both in patients with relapsed or refractory Hodgkin lymphoma. METHODS: In this multicentre, open-label, phase 1/2 trial, patients with relapsed or refractory Hodgkin lymphoma aged 18 years or older who had relapsed after at least one line of therapy, with an Eastern Cooperative Oncology Group performance status of 2 or lower, and adequate organ and marrow function, with no pulmonary dysfunction were eligible for inclusion. Phase 1 primary objectives were to determine the maximum tolerated dose and dose limiting toxicities of brentuximab vedotin combined with ipilimumab (ipilimumab group), nivolumab (nivolumab group), or both (triplet therapy group) using a 3 + 3 dose escalation design with expansion cohorts. During the dose escalation phase, patients were enrolled sequentially into one of six cohorts: in the ipilimumab group fixed brentuximab vedotin 1·8 mg/kg with ipilimumab 1 mg/kg (cohort A) or 3 mg/kg (cohort B); in the nivolumab group fixed nivolumab 3 mg/kg with brentuximab vedotin 1·2 mg/kg (cohort D) or 1·8 mg/kg (cohort E); and in the triplet therapy group fixed nivolumab 3 mg/kg and ipilimumab 1 mg/kg with brentuximab vedotin 1·2 mg/kg (cohort G) or 1·8 mg/kg (cohort H). Additional patients were enrolled in the expansion phase at the same doses of cohorts B, E, and H. All drugs were given intravenously; brentuximab vedotin and nivolumab were given every 3 weeks, ipilimumab was given every 6 weeks in the ipilimumab group and every 12 weeks in the triplet therapy group. All eligible and treated patients were included in the analysis. This phase 1/2 study is registered with ClinicalTrials.gov, NCT01896999. The phase 2, randomised portion of the trial is still enrolling. FINDINGS: Between March 7, 2014, and Dec 28, 2017, 64 patients were enrolled; two patients in the ipilimumab group and one patient in the nivolumab group were excluded due to ineligibility after enrolment and 61 were evaluable. A total of six dose limiting toxicities were reported in four patients, and the doses used in cohorts B, E, and H were established as maximum tolerated doses and patients were subsequently enrolled onto expansion cohorts (C, F, and I) with these schedules. There were ten (43%) grade 3-4 treatment related adverse events in the ipilimumab group, three (16%) in the nivolumab group, and 11 (50%) in the triplet therapy group including: eight (13%) of 64 patients reporting rash, and colitis, gastritis, pancreatitis and arthritis, and diabetic ketoacidosis each occurring in one (2%) patient. There were two (3%) treatment related deaths, one in the nivolumab group and one in the triplet therapy group. The overall response rate was 76% (95% CI 53-92) in the ipilimumab group, 89% (65-99) in the nivolumab group, and 82% (60-95) in the triplet therapy group, and the complete response rate was 57% (95% CI 34-78%) in the ipilimumab group, 61% (36-83%) in the nivolumab group, and 73% (50-89%) in the triplet therapy group. With a median follow-up of 2·6 years (IQR 1·8-2·9) in the ipilimumab group, 2·4 years (2·2-2·6) in the nivolumab group, and 1·7 years (1·6-1·9) in the triplet therapy group, median progression-free survival is 1·2 years (95% CI 1·7-not reached) in the ipilimumab group, but was not reached in the other two treatment groups. Median overall survival has not been reached in any of the groups. INTERPRETATION: There are clear differences in activity and toxicity of the three combination regimens. The tolerability and preliminary activity for the two most active regimens, brentuximab vedotin with nivolumab and the triplet therapy, are being compared in a randomised phase 2 trial (NCT01896999). FUNDING: Eastern Cooperative Oncology Group-American College of Radiology Imaging Network and the National Cancer Institute of the National Institutes of Health.
引用
- Diefenbach CS, Hong F, Ambinder RF, et al. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. Lancet Haematol. 2020. PMID: 32853585. doi:10.1016/S2352-3026(20)30221-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。